BiotechTube
CARR Biosystems

CARR Biosystems

San Francisco, United States· Est.
carrbiosystems.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14.5M

Overview

CARR Biosystems is a pioneering provider of centrifugation equipment for the life sciences, operating as part of the Barry-Wehmiller group. The company offers a unique portfolio of single-use (UniFuge) and stainless steel (PowerFuge, ViaFuge) centrifuges designed for scalable, aseptic bioprocessing from development to commercial manufacturing. With over 25 years of expertise, it serves critical segments like cell/gene therapy and biologics, focusing on contamination reduction and process scalability. Its leadership brings extensive experience from major life sciences firms, positioning the company for growth in the advanced biomanufacturing market.

Medical DevicesDiagnostics

Technology Platform

Scalable centrifugal separation systems including single-use (UniFuge) and stainless steel (PowerFuge, ViaFuge) centrifuges for bioprocessing applications.

Funding History

2
Total raised:$14.5M
Series A$12M
Seed$2.5M

Opportunities

The company is positioned to capitalize on the rapid growth of cell and gene therapies, which heavily rely on gentle, scalable, and sterile separation processes.
The broader industry shift towards single-use technologies and expansion into new fields like cellular agriculture and nucleic acid therapeutics present significant greenfield opportunities for its specialized centrifugation platform.

Risk Factors

CARR faces intense competition from larger, diversified bioprocessing equipment giants with greater resources.
There is also a risk of technological disruption if alternative separation methods gain traction.
Furthermore, its revenue is tied to the capital expenditure cycles of the biopharma industry, which can be volatile.

Competitive Landscape

CARR competes in the bioprocessing equipment market against large, integrated players like Thermo Fisher Scientific, Sartorius, and Danaher (Cytiva), which offer full suites of solutions. Its key differentiation is its specialized focus on centrifugation, particularly its pioneering single-use centrifuge line, which addresses a specific need for contamination-free processing in advanced therapies.

More companies in Digital Health & Biotech SaaS →More companies in United States →